J.P. Bilezikian, L. Bandeira, A. Khan, N.E. Cusano, Hyperparathyroidism. Lancet 391(10116), 168–178 (2018). https://doi.org/10.1016/s0140-6736(17)31430-7
Article CAS PubMed Google Scholar
E. Castellano, R. Attanasio, A. Boriano, M. Pellegrino, G. Borretta, Serum phosphate: a neglected test in the clinical management of primary hyperparathyroidism. J. Clin. Endocrinol. Metab. 107, 612–618 (2022). https://doi.org/10.1210/clinem/dgab676
R. Cunningham, R. Biswas, M. Brazie, D. Steplock, S. Shenolikar, E.J. Weinman, Signaling pathways utilized by PTH and dopamine to inhibit phosphate transport in mouse renal proximal tubule cells. Am. J. Physiol. Ren. Physiol 296, F355–F361 (2009). https://doi.org/10.1152/ajprenal.90426.2008
T. Kawata, Y. Imanishi, K. Kobayashi, T. Miki, A. Arnold, M. Inaba, Y. Nishizawa, Parathyroid hormone regulates fibroblast growth factor-23 in a mouse model of primary hyperparathyroidism. J. Am. Soc. Nephrol. 18, 2683–2688 (2007). https://doi.org/10.1681/asn.2006070783
Article CAS PubMed Google Scholar
M. Peacock, Phosphate metabolism in health and disease. Calcif. Tissue Int. 108, 3–15 (2021). https://doi.org/10.1007/s00223-020-00686-3
Article CAS PubMed Google Scholar
O. Andrukhova, J. Bayer, C. Schüler, U. Zeitz, S.K. Murali, S. Ada, J.M. Alvarez-Pez, A. Smorodchenko, R.G. Erben, Klotho lacks an FGF23-independent role in mineral homeostasis. J. Bone Min. Res. 32, 2049–2061 (2017). https://doi.org/10.1002/jbmr.3195
J.P Bilezikian, M.L Brandi, R Eastell, S.J Silverberg, R Udelsman, C Marcocci, J.T PottsJr, Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop. J. Clin. Endocrinol. Metab. 99, 3561–3569 (2014). https://doi.org/10.1210/jc.2014-1413.
Article CAS PubMed PubMed Central Google Scholar
H. Yamashita, T. Yamashita, M. Miyamoto, T. Shigematsu, J.J. Kazama, T. Shimada, Y. Yamazaki, S. Fukumoto, M. Fukagaw, S. Noguchi, Fibroblast growth factor (FGF)-23 in patients with primary hyperparathyroidism. Eur. J. Endocrinol. 151, 55–60 (2004). https://doi.org/10.1530/eje.0.1510055
Article CAS PubMed Google Scholar
K. Kobayashi, Y. Imanishi, A. Miyauchi, N. Onoda, T. Kawata, H. Tahara, H. Goto, T. Miki, E. Ishimura, T. Sugimoto, T. Ishikawa, M. Inaba, Y. Nishizawa, Regulation of plasma fibroblast growth factor 23 by calcium in primary hyperparathyroidism. Eur. J. Endocrinol. 154, 93–99 (2006). https://doi.org/10.1530/eje.1.02053
Article CAS PubMed Google Scholar
J.E. Witteveen, A.H. van Lierop, S.E. Papapoulos, N.A. Hamdy, Increased circulating levels of FGF23: an adaptive response in primary hyperparathyroidism? Eur. J. Endocrinol. 166, 55–60 (2012). https://doi.org/10.1530/eje-11-0523
Article CAS PubMed Google Scholar
C. Cipriani, J. Pepe, L. Colangelo, V. Fassino, M. Occhiuto, P. Biondi, L. Nieddu, S. Minisola, Investigating subtle kidney injury in primary hyperparathyroidism by means of sensitive and specific biomarkers. Clin. Endocrinol. 91, 660–668 (2019). https://doi.org/10.1111/cen.14064
P.J. Tebben, R.J. Singh, B.L. Clarke, R. Kumar, Fibroblast growth factor 23, parathyroid hormone, and 1alpha,25-dihydroxyvitamin D in surgically treated primary hyperparathyroidism. Mayo Clin. Proc. 79, 1508–1513 (2004). https://doi.org/10.4065/79.12.1508
Article CAS PubMed Google Scholar
I.L. Nilsson, S. Norenstedt, F. Granath, J. Zedenius, Y. Pernow, T.E. Larsson, FGF23, metabolic risk factors, and blood pressure in patients with primary hyperparathyroidism undergoing parathyroid adenomectomy. Surgery 159, 211–217 (2016). https://doi.org/10.1016/j.surg.2015.06.057
S.K. Bhadada, J. Ghosh, R. Pal, S. Mukherjee, Phosphate: an underrated component of primary hyperparathyroidism. Best. Pract. Res. Clin. Endocrinol. Metab. 38, 101837 (2024). https://doi.org/10.1016/j.beem.2023.101837
Article CAS PubMed Google Scholar
D. Rendina, T. Esposito, G. Mossetti, G. De Filippo, F. Gianfrancesco, A. Perfetti, S. Magliocca, P. Formisano, D. Prié, P. Strazzullo, A functional allelic variant of the FGF23 gene is associated with renal phosphate leak in calcium nephrolithiasis. J. Clin. Endocrinol. Metab. 97, 840–844 (2012). https://doi.org/10.1210/jc.2011-1528
F.P. Cappuccio, P. Strazzullo, M. Mancini, Kidney stones and hypertension: population-based study of an independent clinical association. BMJ 300, 1234–1236 (1990). https://doi.org/10.1136/bmj.300.6734.1234
Article CAS PubMed PubMed Central Google Scholar
S. Gonnelli, C. Caffarelli, S. Cappelli, S. Rossi, N. Giordano, R. Nuti, Gender-specific associations of appendicular muscle mass with BMD in elderly Italian subjects. Calcif. Tissue Int. 95, 340–348 (2014). https://doi.org/10.1007/s00223-014-9902-3
Article CAS PubMed Google Scholar
R.J. Walton, O.L. Bijvoet, Nomogram for derivation of renal threshold phosphate concentration. Lancet 306, 309–310 (1975). https://doi.org/10.1016/s0140-6736(75)92736-1
J.A. Kanis, E.V. McCloskey, H. Johansson, A. Oden, L.J. Melton, N. Khaltaev, A reference standard for the description of osteoporosis. Bone 42, 467–475 (2008). https://doi.org/10.1016/j.bone.2007.11.001
Article CAS PubMed Google Scholar
S. Baim, N. Binkley, J.P. Bilezikian et al. Official positions of the international society for clinical densitometry and executive summary of the 2007 ISCD position development conference. J. Clin. Densitom. 11, 75–91 (2008). https://doi.org/10.1016/j.jocd.2007.12.007
G. Guglielmi, G.M. Giannatempo, B.A. Blunt, S. Grampp, C.C. Glüer, M. Cammisa, H.K. Genant, Spinal bone mineral density by quantitative CT in a normal Italian population. Eur. Radiol. 5, 269–275 (1995). https://doi.org/10.1007/BF00185311
H.K. Genant, C.Y. Wu, C. van Knijk, M. Nevitt, Vertebral fracture assessment using a semi-quantitative technique. J. Bone Min. Res. 8, 1137–1148 (1993). https://doi.org/10.1002/jbmr.5650080915
D. Prié, P. Ureña Torres, G. Friedlander, Fibroblast growth factor 23-Klotho: a new axis of phosphate balance control. Med. Sci. 25, 489–495 (2009). https://doi.org/10.1051/medsci/2009255489
H. Nishi, T. Nii-Kono, S. Nakanishi, Y. Yamazaki, T. Yamashita, S. Fukumoto, K. Ikeda, A. Fujimori, M. Fukagawa, Intravenous calcitriol therapy increases serum concentrations of fibroblast growth factor-23 in dialysis patients with secondary hyperparathyroidism. Nephron Clin. Pract. 101, c94–c99 (2005). https://doi.org/10.1159/000086347
Article CAS PubMed Google Scholar
C. Su, L. Meng, S.Z. Trooskin, S.A. Shapses, Y. He, A. Al-Dayyeni, X. Wang, Serum klotho levels in primary hyperparathyroidism patients before and after parathyroidectomy. Endocrine 70, 421–425 (2020). https://doi.org/10.1007/s12020-020-02427-w
Article CAS PubMed Google Scholar
M. Sykała, P. Szumowski, M. Mojsak, S. Abdelrazek, Ł. Żukowski, D. Lipińska, I. Juchnicka, G. Kozłowska, M. Szelachowska, A. Krętowski, J. Myśliwiec, Assessment of clinical utility of assaying FGF-23, klotho protein, osteocalcin, NTX, and sclerostin in patients with primary hyperparathyroidism. J. Clin. Med. 10, 3089 (2021). https://doi.org/10.3390/jcm10143089
Article CAS PubMed PubMed Central Google Scholar
F. De Lucia, S. Minisola, E. Romagnoli, J. Pepe, C. Cipriani, A. Scillitani, N. Parikh, D.S. Rao, Effect of gender and geographic location on the expression of primary hyperparathyroidism. J. Endocrinol. Invest. 36, 123–126 (2013). https://doi.org/10.3275/8455
Article CAS PubMed Google Scholar
E. Castellano, R. Attanasio, A. Boriano, M. Pellegrino, F. Garino, L. Gianotti, G. Borretta, Sex difference in the clinical presentation of primary hyperparathyroidism: influence of menopausal status. J. Clin. Endocrinol. Metab. 102, 4148–4152 (2017). https://doi.org/10.1210/jc.2017-01080
J. Wang, S. Shete, A test for genetic association that incorporates information about deviation from Hardy-Weinberg proportions in cases. Am. J. Hum. Genet. 83, 53–63 (2008). https://doi.org/10.1016/j.ajhg.2008.06.010
Comments (0)